All In Biotech

Drug Trial Radar · NCT00772603

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Feb 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 366 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

366

Actual

Start

Nov 2008

Primary completion

Apr 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Parexel
First posted
Oct 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures

Conditions

  • Epilepsies, Partial

Interventions

  • PlaceboDrug

    Non-active tablet identical to study drug tablets

  • 2400mg SPN-804Drug

    tablets containing 600mg OXC XR, identical to non-active tablets

  • 1200mg SPN-804Drug

    two active tablets and two non-active tablets, all identical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PCH(T), ITTTime frame: Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline

Locations

71 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Northport, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Riverside, California

  • Site not named

    West Los Angeles, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Springfield, Illinois

  • Site not named

    Lexington, Kentucky

  • Site not named

    Bethesda, Maryland

  • Site not named

    Missoula, Montana

  • Site not named

    Camden, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Baytown, Texas

  • Site not named

    Temple, Texas

  • Site not named

    Blagoevgrad, Bulgaria

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Greenfield Park, Quebec, Canada

  • Site not named

    Dubrovnik, Croatia

  • Site not named

    Rijeka, Croatia

  • Site not named

    Zadar, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Aguascalientes, Aguascalientes, Mexico

  • Site not named

    Chihuahua City, Chihuahua, Mexico

  • Site not named

    Ciudad Juárez, Chihuahua, Mexico

  • Site not named

    Durango, Durango, Mexico

  • Site not named

    Guadalajara, Jalisco, Mexico

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.